Brian Stuart Lucas

This inventor holds 21 USPTO granted patents and 41 published patent applications, plus 3 CIPO patents and 22 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Biogen Ma Inc., Skyhawk Therapeutics, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Stuart Lucas. Retrieved from https://idiyas.com/inventor/brian-stuart-lucas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 41)

% Patents Active = 95.2

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 22 (Patent Applications = 54)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 37(Granted Patents)

Location History:

San Francisco, CA (US) (2013 - 2016)
Thousand Oaks, CA (US) (2021)
Cambridge, MA (US) (2019 - 2022)
Arlington, MA (US) (2017 - 2024)

Company Filing History:

Skyhawk Therapeutics, Inc.

patents

4. 2 out of 490

The Broad Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Splicing Modulation

GSK3 Inhibitors

Nrf2 Activators

MDM2 Inhibitors

Piperidinone Derivatives

Heterocyclic Compounds

IRAK4 Inhibitors

Mcl-1 Protein

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12522597 - METHODS AND COMPOSITIONS FOR MODULATING SPLICING (2026-01-13),

2. 12509460 - METHODS AND COMPOSITIONS FOR MODULATING SPLICING (2025-12-30),

3. 12486289 - Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof (2025-12-02),

4. 11964971 - Methods and compositions for modulating splicing (2024-04-23),

5. 11845744 - Methods and compositions for modulating splicing (2023-12-19),

6. 11465963 - Tetrahydronaphthalene derivatives useful as Nrf2 activators (2022-10-11),

7. 11427561 - IRAK4 inhibiting agents (2022-08-30),

8. 11203601 - Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof (2021-12-21),

9. 11001598 - Compounds that inhibit Mcl-1 protein (2021-05-11),

10. 10968181 - NRF2 activator (2021-04-06),

11. 10836779 - Compounds that inhibit MCL-1 protein (2020-11-17),

12. 10577367 - IRAK4 inhibiting agents (2020-03-03),

13. 10246456 - IRAK4 inhibiting agents (2019-04-02),

14. 10100063 - Compounds that inhibit Mcl-1 protein (2018-10-16),

15. 9873704 - Heterocyclic compounds and their uses (2018-01-23),

Title: Brian Stuart Lucas: Innovator at Amgen Inc.

Introduction

Brian Stuart Lucas is a notable inventor based in San Francisco, California. He currently works at Amgen Inc., a leading biotechnology company. Although he holds no patents to his name, his contributions to the field of biotechnology are significant.

Latest Patents

As of now, Brian Stuart Lucas has not registered any patents. However, his work at Amgen Inc. involves innovative research and development in the biotechnology sector.

Career Highlights

Brian has built a career focused on advancing biotechnological solutions. His role at Amgen Inc. allows him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking projects.

Collaborations

Some of his coworkers include Michael David Bartberger and Ana Gonzalez Buenrostro. Together, they work on various projects that aim to push the boundaries of biotechnology.

Conclusion

Brian Stuart Lucas is an influential figure in the biotechnology field, contributing to innovative research at Amgen Inc. His collaborative efforts with talented colleagues further enhance the impact of his work.

Profile summary based on public USPTO records.